Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03680404 · ClinicalTrials.gov registry record · Phase 1

The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction

A Phase 1 study, sponsored by The University of Texas at Arlington.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT03680404 is a Phase 1 study that has completed, run by The University of Texas at Arlington. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03680404, a Phase 1 study, has completed, sponsored by The University of Texas at Arlington.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

The goal of this study is to examine possible mechanisms of heightened vasoconstriction in Black/African American men and women as possible links to the elevated prevalence of cardiovascular dysfunction and disease. The main targets in this study are sources of oxidative stress.

Interventions

  • DRUG Control (Phenylephrine)
  • DRUG Phenylephrine + Apocynin
  • DRUG Phenylephrine + Allopurinol
  • DRUG Phenylephrine + Tempol

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2018-10-01
Est. Completion 2020-02-01
Phase Phase 1

What the Registry Record Tells You About NCT03680404

The ClinicalTrials.gov registry entry for NCT03680404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas at Arlington, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Control (Phenylephrine) is the first listed.

NCT03680404 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03680404 about?

NCT03680404 is a clinical study titled "The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction". The goal of this study is to examine possible mechanisms of heightened vasoconstriction in Black/African American men and women as possible links to the elevated prevalence of cardiovascular dysfunction and disease. The main targets in this study are sources of oxidative stress.

What is the current status of trial NCT03680404?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-10-01. Estimated completion is 2020-02-01.

What interventions are being tested in trial NCT03680404?

The interventions under investigation include: Control (Phenylephrine) (DRUG), Phenylephrine + Apocynin (DRUG), Phenylephrine + Allopurinol (DRUG), Phenylephrine + Tempol (DRUG).

Who is sponsoring clinical trial NCT03680404?

This trial is sponsored by The University of Texas at Arlington, which has 32 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.